Cipla, Boehringer Ingelheim to co-market oral anti-diabetic drugs Oboravo, Oboravo Met, Tiptengio

As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes, ranking second behind China; and is poised to reach 134.2 million patients by 2045. Fortunately, while the number of patients is increasing, so is the awareness among the public to address it. The Indian diabetes market is valued at INR 1,45,451 million and is growing at 10.35% (IMS MAT May 2020) with the oral anti-diabetic market being valued at INR 1,07,354 million and growing at 11.34% (IMS MAT May 2020).

Commenting on the partnership, Nikhil Chopra, Executive Vice President & CEO - India Business, Cipla said, "We are committed to providing access to innovative medications that address unmet patient needs. Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access, and reach capabilities, we will be at the forefront of providing holistic diabetes care."

Commenting on the expanded partnership, Mr Sharad Tyagi, Managing Director - Boehringer Ingelheim India said, "We are excited about the expansion of our partnership with Cipla to provide pioneering medicines through the new oral anti-diabetic drugs. As a dedicated organization to the field of diabetes, we aim to provide wider access and innovative solutions to the medical fraternity and patients with one of the most comprehensive Diabetes portfolios in the country."

Read also: Cipla to knock out Hetero Healthcare in pricing battle of Remdesivir?